Multisite phosphorylation and the integration of stress signals at p53.

The p53 tumour suppressor protein is a potent transcription factor that plays a major role in the defence against tumour development. p53 exists in a latent form that can be activated by a range of stresses including DNA damage, hypoxia, cytokines, metabolic changes, viral infection, and activated oncogenes. Activation of p53 can lead to cellular growth arrest prior to entry into either S phase or mitosis or can trigger cell death through apoptosis. The modification of p53 by multisite phosphorylation provides a potential link between stress signalling and the regulation of p53 activity, and there is now striking evidence that agents that activate p53 can lead to selective changes in its phosphorylation status. Topologically, the phosphorylation sites in p53 fall into two discrete functional domains. Four phosphorylation events take place within the N-terminal 83 amino acids containing the transactivation domain and a region involved in transcription-independent growth suppression. At least three of these modifications occur in response to agents that cause cellular stress such as DNA damage. At the C-terminus, there are three phosphorylation events, each of which can independently regulate the specific DNA-binding function of p53, suggesting convergent control by different signalling pathways. The multiplicity of these covalent modifications and their responsiveness to a wide range of signals suggest that p53 activity is tightly and coordinately controlled in response to stresses and changes in the cellular environment.

[1]  D. Meek,et al.  Phosphorylation of the p53 tumour-suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme. , 1992, Oncogene.

[2]  C. Prives,et al.  Activation of p53 sequence-specific DNA bindingby short single strands of DNA requires the p53 C-terminus , 1995, Cell.

[3]  G. Chu,et al.  DNA-dependent protein kinase is not required for accumulation of p53 or cell cycle arrest after DNA damage. , 1997, Cancer research.

[4]  C. Miller,et al.  The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription , 1993, Molecular and cellular biology.

[5]  W. Deppert,et al.  Negative feedback regulation of wild‐type p53 biosynthesis. , 1995 .

[6]  R. Carroll,et al.  Mapping of phosphomonoester and apparent phosphodiester bonds of the oncogene product p53 from simian virus 40-transformed 3T3 cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[8]  D. Virshup,et al.  Control of simian virus 40 DNA replication by the HeLa cell nuclear kinase casein kinase I , 1993, Molecular and cellular biology.

[9]  P. Shaw,et al.  Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  V. Rotter,et al.  Accumulation of wild‐type p53 protein upon gamma‐irradiation induces a G2 arrest‐dependent immunoglobulin kappa light chain gene expression. , 1995, The EMBO journal.

[11]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[12]  Peter A. Hall,et al.  EDITORIAL. p53—INTEGRATING THE COMPLEXITY , 1996 .

[13]  C. Finlay,et al.  The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth , 1993, Molecular and cellular biology.

[14]  E. Winchester,et al.  Inhibition of DNA replication factor RPA by p53 , 1993, Nature.

[15]  C. Prives,et al.  Increased and altered DNA binding of human p53 by S and G2/M but not Gl cyclin-dependent kinases , 1995, Nature.

[16]  C. Slaughter,et al.  Purification of casein kinase I and isolation of cDNAs encoding multiple casein kinase I-like enzymes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[18]  M. Hoekstra,et al.  Characterization of two protein kinases from Schizosaccharomyces pombe involved in the regulation of DNA repair. , 1994, The EMBO journal.

[19]  C. Delphin,et al.  Casein kinase II and the tumor suppressor protein P53 associate in a molecular complex that is negatively regulated upon P53 phosphorylation. , 1992, The Journal of biological chemistry.

[20]  A. Levine,et al.  Regulation of Transcription Functions of the p53 Tumor Suppressor by the mdm-2 Oncogene , 1995, Molecular medicine.

[21]  D. Meek,et al.  Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53. , 1992, Nucleic acids research.

[22]  U. Knippschild,et al.  p53 N-terminus-targeted protein kinase activity is stimulated in response to wild type p53 and DNA damage. , 1996, Oncogene.

[23]  U. Knippschild,et al.  p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs , 1997, Oncogene.

[24]  C. Marshall,et al.  MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. , 1994, Current opinion in genetics & development.

[25]  G. Landes,et al.  Isolation and Characterization of Human Casein Kinase Iε (CKI), a Novel Member of the CKI Gene Family (*) , 1995, The Journal of Biological Chemistry.

[26]  P. Jeggo,et al.  DNA-dependent protein kinase activity is absent in xrs-6 cells: implications for site-specific recombination and DNA double-strand break repair. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Cohen,et al.  The search for physiological substrates of MAP and SAP kinases in mammalian cells. , 1997, Trends in cell biology.

[28]  G. Lozano,et al.  Analysis of p53 mutants for transcriptional activity , 1991, Molecular and cellular biology.

[29]  X. Chen,et al.  Cooperative DNA binding of p53 with TFIID (TBP): a possible mechanism for transcriptional activation. , 1993, Genes & development.

[30]  D. Lane A death in the life of p53 , 1993, Nature.

[31]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[32]  D. Lane,et al.  Activation of the cryptic DNA binding function of mutant forms of p53. , 1993, Nucleic acids research.

[33]  C. Sunkel,et al.  The casein kinase 1 alpha gene of Drosophila melanogaster is developmentally regulated and the kinase activity of the protein induced by DNA damage. , 1996, Journal of cell science.

[34]  U. Ramsperger,et al.  p53‐catalyzed annealing of complementary single‐stranded nucleic acids. , 1993, The EMBO journal.

[35]  P. Branton,et al.  Regulation of apoptosis by viral gene products , 1997, Journal of virology.

[36]  I. Takenaka,et al.  Regulation of the Sequence-specific DNA Binding Function of p53 by Protein Kinase C and Protein Phosphatases (*) , 1995, The Journal of Biological Chemistry.

[37]  K. Scheidtmann,et al.  Phosphorylation studies on rat p53 using the baculovirus expression system. Manipulation of the phosphorylation state with okadaic acid and influence on DNA binding. , 1995, European journal of biochemistry.

[38]  F. Heffron,et al.  HRR25, a putative protein kinase from budding yeast: association with repair of damaged DNA , 1991, Science.

[39]  P. Friedman,et al.  Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  W Eckhart,et al.  Phosphorylation sites in the amino-terminal region of mouse p53. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Lord,et al.  Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vitro, but not in vivo, even after stimulation with the phorbol ester o-tetradecanoylphorbol 13-acetate. , 1996, Oncogene.

[42]  L. Donehower,et al.  p53 is required for both radiation-induced differentiation and rescue of V(D)J rearrangement in scid mouse thymocytes. , 1996, Genes & development.

[43]  C. Anderson Protein kinases and the response to DNA damage. , 1994, Seminars in cell biology.

[44]  S. Jackson,et al.  The role of Ataxia telangiectasia and the DNA-dependent protein kinase in the p53-mediated cellular response to ionising radiation. , 1996, Oncogene.

[45]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[46]  J. Lord,et al.  Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. , 1997, Molecular pathology : MP.

[47]  A. Levine,et al.  Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[48]  K. Sakaguchi,et al.  Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53 , 1992, Molecular and cellular biology.

[49]  R. Weinberg,et al.  Cell-cycle control and its watchman , 1996, Nature.

[50]  M. Kastan,et al.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[51]  M. Oren,et al.  Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. , 1993, Oncogene.

[52]  K. Kinzler,et al.  Life (and death) in a malignant tumour , 1996, Nature.

[53]  Carissa A. Sanchez,et al.  A p53-dependent mouse spindle checkpoint , 1995, Science.

[54]  D. Meek,et al.  Phosphorylation of p53 in normal and simian virus 40-transformed NIH 3T3 cells , 1988, Molecular and cellular biology.

[55]  M. Evans,et al.  p53 modulation of TFIIH–associated nucleotide excision repair activity , 1995, Nature Genetics.

[56]  M. Oren,et al.  p53 in growth control and neoplasia. , 1996, Biochimica et biophysica acta.

[57]  C. Anderson,et al.  Human cells contain a DNA-activated protein kinase that phosphorylates simian virus 40 T antigen, mouse p53, and the human Ku autoantigen , 1990, Molecular and cellular biology.

[58]  S. D. Gross,et al.  Cell cycle-dependent localization of casein kinase I to mitotic spindles. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[59]  L. Szekely,et al.  p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. , 1995, Nucleic acids research.

[60]  K. Scheidtmann,et al.  p53 phosphorylation mutants retain transcription activity. , 1995, Oncogene.

[61]  R. Tjian,et al.  p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. , 1995, Science.

[62]  D. Meek,et al.  The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. , 1990, The EMBO journal.

[63]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[64]  M. Fiscella,et al.  Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[65]  D. Lane,et al.  Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. , 1994, Cold Spring Harbor symposia on quantitative biology.

[66]  D. Meek Post-translational modification of p53. , 1994, Seminars in cancer biology.

[67]  D. Meek,et al.  Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases. , 1994, The Journal of biological chemistry.

[68]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.

[69]  P. Jeggo,et al.  DNA double-strand break repair and V(D)J recombination: involvement of DNA-PK. , 1995, Trends in biochemical sciences.

[70]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[71]  J. Danska,et al.  V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. , 1996, Genes & development.

[72]  M. Kapoor,et al.  Mutation of Phosphoserine 389 Affects p53 Function in Vivo* , 1996, The Journal of Biological Chemistry.

[73]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[74]  M. Subler,et al.  p53 binds to the TATA-binding protein-TATA complex. , 1993, The Journal of biological chemistry.

[75]  M. Lohrum,et al.  Complex regulation of the DNA-binding activity of p53 by phosphorylation: differential effects of individual phosphorylation sites on the interaction with different binding motifs. , 1996, Oncogene.

[76]  T. Soussi,et al.  Structural aspects of the p53 protein in relation to gene evolution: a second look. , 1996, Journal of molecular biology.

[77]  D. Meek,et al.  p53 Is Phosphorylated in Vitro and in Vivo by an Ultraviolet Radiation-induced Protein Kinase Characteristic of the c-Jun Kinase, JNK1 (*) , 1995, The Journal of Biological Chemistry.

[78]  M. Fiscella,et al.  The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities. , 1994, Oncogene.

[79]  S. Jackson,et al.  The recognition of DNA damage. , 1996, Current opinion in genetics & development.

[80]  D. Grunwald,et al.  Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[81]  D. Meek,et al.  Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. , 1996, Nucleic acids research.

[82]  D. Lane,et al.  Two Distinct Signaling Pathways Activate the Latent DNA Binding Function of p53 in a Casein Kinase II-independent Manner (*) , 1995, Journal of Biological Chemistry.

[83]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[84]  T. Crook,et al.  Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. , 1994, Oncogene.

[85]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[86]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[87]  A. Levine,et al.  p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches , 1995, Cell.

[88]  C. Delphin,et al.  The protein kinase C activator, phorbol ester, cooperates with the wild-type p53 species of Ras-transformed embryo fibroblasts growth arrest. , 1994, The Journal of biological chemistry.

[89]  M. Botchan,et al.  The acidic transcriptional activation domains of VP16 and p53 bind the cellular replication protein A and stimulate in vitro BPV-1 DNA replication , 1993, Cell.

[90]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[91]  C. Hagedorn,et al.  Molecular cloning, expression, and characterization of a 49-kilodalton casein kinase I isoform from rat testis. , 1993, The Journal of biological chemistry.

[92]  Y. Tan,et al.  Okadaic acid mimics multiple changes in early protein phosphorylation and gene expression induced by tumor necrosis factor or interleukin-1. , 1992, The Journal of biological chemistry.

[93]  F. Alt,et al.  Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation , 1995, Cell.

[94]  D. Ward,et al.  Gene for the catalytic subunit of the human DNA-activated protein kinase maps to the site of the XRCC7 gene on chromosome 8. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[95]  M. Montenarh,et al.  Association of casein kinase II with immunopurified p53. , 1991, Oncogene.

[96]  R. Pepperkok,et al.  Casein kinase II is required for transition of G0/G1, early G1, and G1/S phases of the cell cycle. , 1994, The Journal of biological chemistry.

[97]  S. Fields,et al.  Presence of a potent transcription activating sequence in the p53 protein. , 1990, Science.

[98]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[99]  L. Tack,et al.  Altered phosphorylation of free and bound forms of monkey p53 and simian virus 40 large T antigen during lytic infection , 1992, Journal of virology.

[100]  T. Jacks,et al.  Mutations in the p53 and SCID genes cooperate in tumorigenesis. , 1996, Genes & development.

[101]  E. Appella,et al.  Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. , 1992, Oncogene.

[102]  A. Levine,et al.  Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells , 1982, Cell.

[103]  C. Ingles,et al.  The transactivator proteins VP16 and GAL4 bind replication factor A , 1993, Cell.

[104]  A. Levine,et al.  Human TAFII31 protein is a transcriptional coactivator of the p53 protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[105]  K. Vousden,et al.  Transcriptional activation by p53 correlates with suppression of growth but not transformation , 1994, Cell.

[106]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[107]  S. E. Lee,et al.  Evidence for DNA-PK-dependent and -independent DNA double-strand break repair pathways in mammalian cells as a function of the cell cycle , 1997, Molecular and cellular biology.

[108]  C. Anderson,et al.  DNA damage and the DNA-activated protein kinase. , 1993, Trends in biochemical sciences.